Long-Term Immunogenicity after One and Two Doses of a Monovalent MF59-Adjuvanted A/H1N1 Influenza Virus Vaccine Coadministered with the Seasonal 2009-2010 Nonadjuvanted Influenza Virus Vaccine in HIV-Infected Children, Adolescents, and Young Adults in a Randomized Controlled Trial
Articolo
Data di Pubblicazione:
2011
Citazione:
Long-Term Immunogenicity after One and Two Doses of a Monovalent MF59-Adjuvanted
A/H1N1 Influenza Virus Vaccine Coadministered with the Seasonal 2009-2010
Nonadjuvanted Influenza Virus Vaccine in HIV-Infected Children, Adolescents, and
Young Adults in a Randomized Controlled Trial / A. Viganò, V. Giacomet, E. Pariani, E. Giani, V. Manfredini, G. Bedogni, P. Erba, A. Amendola, A. Zanetti, G.V. Zuccotti. - In: CLINICAL AND VACCINE IMMUNOLOGY. - ISSN 1556-6811. - 18:9(2011), pp. 1503-1509.
Abstract:
Few data are available on the safety and long-term immunogenicity of A/H1N1
pandemic influenza vaccines for HIV-infected pediatric patients. We performed a
randomized controlled trial to evaluate the safety and long-term immunogenicity
of 1 versus 2 doses of the 2009 monovalent pandemic influenza A/H1N1
MF59-adjuvanted vaccine (PV) coadministered with the seasonal 2009-2010 trivalent
nonadjuvanted influenza vaccine (SV) to HIV-infected children, adolescents, and
young adults. A total of 66 HIV-infected patients aged 9 to 26 years were
randomized to receive one (group 1) or two (group 2) doses of PV coadministered
with 1 dose of SV. The main outcome was the seroconversion rate for PV at 1
month. Secondary outcomes were the geometric mean titer ratios and the
seroprotection rates at 1 month for all vaccines, seroconversion rates at 1 month
for SV, and longitudinal changes of antibody titers (ABTs) at 1, 2, 6, and 12
months for all vaccines. Groups 1 and 2 had similar CD4 counts and HIV RNA levels
during the study. The seroconversion rate for PV was 100% at 1 month in both
groups. ABTs for PV were high during the first 6 months and declined below
seroprotection levels thereafter. Longitudinal changes in ABTs were similar in
groups 1 and 2 for both PV and SV. The side effects of vaccination were mild and
mostly local. In HIV-infected children, adolescents, and young adults, the immune
response triggered by a single dose of PV was similar to that obtained with a
double dose and was associated with long-term antibody response.
Tipologia IRIS:
01 - Articolo su periodico
Elenco autori:
A. Viganò, V. Giacomet, E. Pariani, E. Giani, V. Manfredini, G. Bedogni, P. Erba, A. Amendola, A. Zanetti, G.V. Zuccotti
Link alla scheda completa: